Rivaroxaban

每周药品注册获批数据，分门别类呈现，一目了然。(5.19-5.25）新药上市申请药品名称企业注册分类受理号HSK21542注射液辽宁海思科制药有限公司1CXHS2300094吡罗西尼片轩竹生物科技股份有限公司1CXHS2300093吡罗西尼片轩竹生物科技股份有限公司1CXHS2300075盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHS2400069盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHS2400068盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHS2400067注射用维拉苷酶β北海康成(上海)生物科技有限公司1CXSS2400119贝莫苏拜单抗注射液正大天晴药业集团南京顺欣制药有限公司2.2CXSS2400082注射用卡瑞利珠单抗苏州盛迪亚生物医药有限公司2.2CXSS2300091新药临床申请药品名称企业注册分类受理号PRT-064040鼻喷雾剂四川普锐特药业有限公司1CXHL2500257PRT-064040鼻喷雾剂四川普锐特药业有限公司1CXHL2500256PRT-064040鼻喷雾剂四川普锐特药业有限公司1CXHL2500255HS-10510片江苏豪森药业集团有限公司1CXHL2500244HS-10510片江苏豪森药业集团有限公司1CXHL2500243SGB-3383注射液苏州圣因生物医药有限公司1CXHL2500238KEM2418缓释直服颗粒深圳珐玛易药品科技有限公司2.2CXHL2500252利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500250利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500249利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500248利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500247利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500246TAP-1503 乳膏上海泽德曼医药科技有限公司2.4CXHL2500231BPR-102胶囊成都倍特益康恩生物医药科技有限公司1CXSL2500210BPR-102胶囊成都倍特益康恩生物医药科技有限公司1CXSL2500209FB1002重组人源化单克隆抗体注射液福贝生物医药科技(北京)有限公司1CXSL2500192皮炎诊断贴剂02贴浙江我武生物科技股份有限公司1CXSL2500195皮炎诊断贴剂02贴浙江我武生物科技股份有限公司1CXSL2500194皮炎诊断贴剂02贴浙江我武生物科技股份有限公司1CXSL2500193仿制药申请药品名称企业注册分类受理号维生素B6注射液上海禾丰制药有限公司3CYHS2501112氨溴特罗口服溶液湖北欣泽霏药业有限公司3CYHS2400652硫酸镁注射液河北一品制药股份有限公司3CYHS2400554美索巴莫注射液广州合和医药有限公司3CYHS2400448氯化钾颗粒福州基石医药科技有限公司3CYHS2400193氯化钾颗粒福州基石医药科技有限公司3CYHS2400192二羟丙茶碱注射液湖南柏齐鹤药物研发有限公司3CYHS2400173美索巴莫注射液海南普利制药股份有限公司3CYHS2400129醋酸葡萄糖维持液山东科伦药业有限公司3CYHS2400053醋酸葡萄糖维持液山东科伦药业有限公司3CYHS2400054重酒石酸间羟胺注射液武汉久安药业有限公司3CYHS2303676美索巴莫注射液北京沃邦医药科技有限公司3CYHS2303661注射用甲磺酸加贝酯石家庄四药有限公司3CYHS2303631复方电解质醋酸钠注射液山东科伦药业有限公司3CYHS2303623注射用比阿培南/氯化钠注射液湖南科伦制药有限公司3CYHS2303536异烟肼注射液广州绿十字制药股份有限公司3CYHS2303510二羟丙茶碱注射液华夏生生药业(北京)有限公司3CYHS2303378硫酸沙丁胺醇注射液山东华鲁制药有限公司3CYHS2303298二羟丙茶碱注射液武汉华尔生物科技有限公司3CYHS2303282硫酸镁注射液江西博泰药业有限公司3CYHS2303278氟马西尼注射液上海旭东海普药业有限公司3CYHS2303241氟马西尼注射液上海旭东海普药业有限公司3CYHS2303240注射用尼可地尔成都地奥九泓制药厂3CYHS2303209硫酸镁注射液焦作市民康药业有限公司3CYHS2303181甲硫酸新斯的明注射液云南先施药业有限公司3CYHS2303137甲硫酸新斯的明注射液云南先施药业有限公司3CYHS2303136生理氯化钠溶液华夏生生药业(北京)有限公司3CYHS2303121甲硫酸新斯的明注射液杭州民生药业股份有限公司3CYHS2303109甲硫酸新斯的明注射液杭州民生药业股份有限公司3CYHS2303108甲硫酸新斯的明注射液杭州民生药业股份有限公司3CYHS2303107重酒石酸去甲肾上腺素注射液中润药业有限公司3CYHS2303046重酒石酸去甲肾上腺素注射液中润药业有限公司3CYHS2303045地奈德软膏杭州领业医药科技有限公司3CYHS2303027复合磷酸氢钾注射液成都米子生物医药科技有限公司3CYHS2303010复合磷酸氢钾注射液成都欣捷高新技术开发股份有限公司3CYHS2303008酮咯酸氨丁三醇注射液广州一品红制药有限公司3CYHS2303001盐酸丙卡特罗颗粒江苏正大清江制药有限公司3CYHS2302905醋酸钠林格葡萄糖注射液成都赛诺联创生物科技有限公司3CYHS2302812复方电解质醋酸钠葡萄糖注射液仁合益康集团有限公司3CYHS2302807复方电解质醋酸钠葡萄糖注射液仁合益康集团有限公司3CYHS2302806醋酸钙口服溶液河北华晨药业集团有限公司3CYHS2302797盐酸去氧肾上腺素注射液安徽长江药业有限公司3CYHS2302659水合氯醛灌肠剂成都硕德药业有限公司3CYHS2302523利伐沙班颗粒南京海纳制药有限公司3CYHS2302484氯化钙注射液广州合和医药有限公司3CYHS2302480钠钾镁钙注射用浓溶液山东豪瑞恩制药有限公司3CYHS2302447盐酸利多卡因注射液云南药科院生物医药股份有限公司3CYHS2302400注射用阿莫西林钠广州艾奇西新药研究有限公司3CYHS2302386注射用阿莫西林钠广州艾奇西新药研究有限公司3CYHS2302385硫代硫酸钠注射液成都倍特药业股份有限公司3CYHS2302223富马酸酮替芬口服溶液海口天行健药物研究有限公司3CYHS2302211甲硫酸新斯的明注射液宝利化(南京)制药有限公司3CYHS2301868米诺地尔外用溶液浙江高跖医药科技股份有限公司3CYHS2301380卡络磺钠注射液海口天行健药物研究有限公司3CYHS2301262卡络磺钠注射液海口天行健药物研究有限公司3CYHS2301261米诺膦酸片安徽博诺美科生物医药有限公司3CYHS2301180利多卡因凝胶贴膏湖南九典制药股份有限公司3CYHS2300719卡络磺钠注射液四川汇宇海玥医药科技有限公司3CYHS2300666卡络磺钠注射液四川汇宇海玥医药科技有限公司3CYHS2300665依巴斯汀口服溶液南京海纳医药科技股份有限公司3CYHS2300635布洛氢可酮片宜昌人福药业有限责任公司3CYHS2201954国;CYHS2201954布洛氢可酮片宜昌人福药业有限责任公司3CYHS2201953国;CYHS2201953多潘立酮片温州海鹤药业有限公司4CYHS2402862甲泼尼龙片武汉九珑人福药业有限责任公司4CYHS2402356氧(液态)侨源气体(眉山)有限公司4CYHS2402288普拉洛芬滴眼液山东辰欣佛都药业股份有限公司4CYHS2401017沙格列汀二甲双胍缓释片江苏万高药业股份有限公司4CYHS2400993沙格列汀二甲双胍缓释片江苏万高药业股份有限公司4CYHS2400992盐酸伐地那非片江苏万高药业股份有限公司4CYHS2400984盐酸伐地那非片江苏万高药业股份有限公司4CYHS2400982吸入用乙酰半胱氨酸溶液海南皇隆制药股份有限公司4CYHS2400970孟鲁司特钠咀嚼片牡丹江恒远药业股份有限公司4CYHS2400855孟鲁司特钠咀嚼片牡丹江恒远药业股份有限公司4CYHS2400854妥布霉素滴眼液浙江赛默制药有限公司4CYHS2400761马来酸氟伏沙明片合肥英太制药有限公司4CYHS2400736马来酸氟伏沙明片合肥英太制药有限公司4CYHS2400735马来酸氟伏沙明片苏州第三制药厂有限责任公司4CYHS2400617马来酸氟伏沙明片苏州第三制药厂有限责任公司4CYHS2400616硫酸氨基葡萄糖胶囊江苏润邦药业有限公司4CYHS2400579马来酸氟伏沙明片江苏诺泰澳赛诺生物制药股份有限公司4CYHS2400595乙酰半胱氨酸泡腾片浙江赛默制药有限公司4CYHS2400520双氯芬酸钠缓释片锦州奥鸿药业有限责任公司4CYHS2400513双氯芬酸钠缓释片锦州奥鸿药业有限责任公司4CYHS2400512丙戊酸钠口服溶液山东达因海洋生物制药股份有限公司4CYHS2400465盐酸决奈达隆片石家庄四药有限公司4CYHS2400464盐酸奥洛他定滴眼液石家庄格瑞药业有限公司4CYHS2400399溴莫尼定噻吗洛尔滴眼液石家庄格瑞药业有限公司4CYHS2400335盐酸伐地那非片广州绿十字制药股份有限公司4CYHS2400334地夸磷索钠滴眼液深圳市华生元基因工程发展有限公司4CYHS2400318间苯三酚注射液常州四药制药有限公司4CYHS2400234吸入用丙酸倍氯米松混悬液河北创健药业有限公司4CYHS2400231盐酸伊立替康脂质体注射液无锡济煜山禾药业股份有限公司4CYHS2400207盐酸奥洛他定滴眼液乐信乐美(海南)生物科技有限公司4CYHS2400163硫酸氨基葡萄糖胶囊武汉维奥制药有限公司4CYHS2400157地夸磷索钠滴眼液郑州卓峰制药有限公司4CYHS2400151奥美沙坦酯氨氯地平片珠海润都制药股份有限公司4CYHS2400029曲伏噻吗滴眼液山东辰欣佛都药业股份有限公司4CYHS2400034注射用头孢唑肟钠安徽省先锋制药有限公司4CYHS2303664注射用头孢唑肟钠安徽省先锋制药有限公司4CYHS2303663利托那韦片福建广生中霖生物科技有限公司4CYHS2303569左氧氟沙星滴眼液山东辰欣佛都药业股份有限公司4CYHS2303542奥美沙坦酯氨氯地平片宁波大红鹰药业股份有限公司4CYHS2303522注射用盐酸美法仑凯信远达医药(无锡)有限公司4CYHS2303513注射用头孢他啶/氯化钠注射液湖南科伦制药有限公司4CYHS2303472注射用氯诺昔康天津梅花生物医药科技有限公司4CYHS2303416布洛芬混悬滴剂山东新华制药股份有限公司4CYHS2303315布洛芬混悬滴剂山东新华制药股份有限公司4CYHS2303314二甲双胍恩格列净片(I)浙江易泽达医药科技有限公司4CYHS2303310罗沙司他胶囊重庆圣华曦药业股份有限公司4CYHS2303284罗沙司他胶囊重庆圣华曦药业股份有限公司4CYHS2303283苯磺酸左氨氯地平片山东鲁抗医药股份有限公司4CYHS2303187苯磺酸左氨氯地平片山东鲁抗医药股份有限公司4CYHS2303186盐酸贝尼地平片上海安必生制药技术有限公司4CYHS2303185利奈唑胺葡萄糖注射液北京吉洛华制药有限公司4CYHS2303183枸橼酸托法替布片国药集团容生制药有限公司4CYHS2303134盐酸乌拉地尔注射液江苏迪赛诺制药有限公司4CYHS2303114达格列净二甲双胍缓释片(IV)浙江华海药业股份有限公司4CYHS2303039达格列净二甲双胍缓释片(III)浙江华海药业股份有限公司4CYHS2303038达格列净二甲双胍缓释片(I)浙江华海药业股份有限公司4CYHS2303037达格列净二甲双胍缓释片(I)浙江华海药业股份有限公司4CYHS2303036黄体酮软胶囊浙江仙琚制药股份有限公司4CYHS2302889黄体酮软胶囊浙江仙琚制药股份有限公司4CYHS2302888碘普罗胺注射液博瑞制药(苏州)有限公司4CYHS2302630碘普罗胺注射液博瑞制药(苏州)有限公司4CYHS2302629注射用硼替佐米瑞阳制药股份有限公司4CYHS2302231莫匹罗星软膏海南紫程众投生物科技有限公司4CYHS2302106注射用头孢哌酮钠舒巴坦钠浙江惠迪森药业有限公司4CYHS2302052盐酸度洛西汀肠溶胶囊北京四环制药有限公司4CYHS2300590盐酸度洛西汀肠溶胶囊北京四环制药有限公司4CYHS2300589盐酸度洛西汀肠溶胶囊北京四环制药有限公司4CYHS2300588多种油脂肪乳注射液(C6-24)四川科伦药业股份有限公司4CYHL2500048多种油脂肪乳注射液(C6-24)四川科伦药业股份有限公司4CYHL2500047进口申请药品名称企业注册分类受理号盐酸阿思尼布片Novartis Pharma Schweiz AG2.4JXHS2400043琥珀酸瑞波西利片Novartis Pharma Schweiz AG2.4JXHS2300126乙酰半胱氨酸注射液Zambon Switzerland Ltd.5.1JXHS2200025国;JXHS2200025注射用替奈普酶Boehringer Ingelheim International GmbH2.2JXSS2400001注射用坦昔妥单抗Incyte Biosciences Distribution B.V.3.1JXSS2400050MK-7240注射液Merck Sharp & Dohme LLC1JXSL2500037中药相关申请药品名称企业注册分类受理号开心散上海和黄药业有限公司3.1CXZS2400024注：橙色字体部分结论为不批准或收到通知件；

Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Patients on the Blood Thinner, Ticagrelor, with CytoSorbents Therapy PRINCETON, N.J., May 22, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today's presentation at EuroPCR 2025 of a new contemporary real-world data analysis highlighting the intraoperative use of its technology to significantly reduce the severity of bleeding in urgent coronary artery bypass grafting (CABG) patients on the blood thinner, ticagrelor (Brilinta®, AstraZeneca) who had not completed the recommended drug washout period. Presented by Professor Robert F. Storey, Academic Director and Honorary Consultant Interventional Cardiologist for the Cardiology and Cardiothoracic Surgery Directorate, Sheffield Teaching Hospitals NHS Foundation Trust (U.K.) and co-Principal Investigator of the international STAR (Safe and Timely Antithrombotic Removal) Registry, the findings were shared during the session titled, "Ticagrelor Removal to Reduce Bleeding after Urgent CABG: Comparative Analysis of Real-world Data." Key Study Insights The analysis compared two patient populations undergoing urgent CABG surgery on ticagrelor before completing the guideline-recommended 3-day washout period. The device group consisted of an updated cohort of 150 patients from the STAR Registry who were all operated on with the use of CytoSorbents' device, while the control group comprised 644 similar patients from a recent publication who were all operated on without the use of the device. The results showed statistically significant and clinically meaningful reductions in severe bleeding complications with device use, including: Reductions in the rate of BARC-4 (validated measure of severe bleeding after CABG) severe bleeding: 10.7% vs. 33% control, p<0.001) Reduction in large transfusion events (≥5 units of blood): 6% vs. 27% control, p<0.001) Reduction in the need for re-operations to control bleeding (4% vs. 9.6% control, p=0.02) Importantly, no device-related adverse events or device deficiencies were reported by participating centers, underscoring the device's ease-of-use and safety in real-world clinical practice. Professor Storey concluded his presentation, stating, "A device that removes free ticagrelor from blood and is easily integrated into the CPB circuit appears safe and effective in mitigating excess bleeding in ticagrelor-treated patients undergoing CABG surgery before completing the 3-day washout," Dr. Efthymios Deliargyris, MD, Chief Medical Officer of CytoSorbents stated, "Today's presentation in Paris is a vital addition to the growing evidence base of blood thinner removal with our technology. The data show that device use is simple and safe but more importantly establish that patients on ticagrelor undergoing urgent CABG at heart centers using our device as part of their standard care, experience significantly lower bleeding complications compared to patients operated without the device. We are thrilled with these new data that support routine use of our device as an effective solution to address the major unmet medical need of patients on blood thinners like ticagrelor requiring urgent cardiac surgery." Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, noted, "We are proud to see the updated STAR Registry data presented alongside one of the largest and most recent meta-analyses of non-device treated CABG patients on Brilinta®. With growing adoption of our technology by cardiac surgery centers worldwide, this important real-world evidence from our registry reinforces the clinical value of our therapy that we hope to bring to all countries and patients around the world." Additional Presentation and Study Details In today's oral presentation titled "Ticagrelor Removal to Reduce Bleeding after Urgent CABG: Comparative Analysis of Real-world Data" at the 2025 EuroPCR conference in Paris, France, the world-leading course in interventional cardiovascular medicine with over 12,000 attendees, Professor Robert Storey presented the results of a comparative analysis in patients on ticagrelor undergoing CABG surgery before completing the recommended three-day washout period with or without the intraoperative use of the CytoSorb® device. Device group: 150 patients from the STAR Registry that is actively enrolling at 28 sites in 6 European countries (Germany, United Kingdom, Austria, Belgium, Sweden and Switzerland) who were all operated with the use of the device Control group: 644 similar patients from the recently published individual patient data meta-analysis in the peer-reviewed journal, European Journal of Cardiothoracic Surgery, who were all operated without the use of the device Key Data Highlights: There were no significant differences in baseline characteristics between the two groups (device vs. control), including age (65 vs. 67 years), acute coronary syndrome presentation (90.5% vs. 89.1%) and overall perioperative risk according to Euroscore II (2.5 vs. 2.8%). Most importantly, the two groups had near identical distribution of the time of CABG relative to the last dose of ticagrelor, a very strong factor determining bleeding risk (within 1 day of last dose 41.4% vs. 41.9%, more than 1 but less than 3 days 58.6% vs. 58.1%). The primary outcome of the analysis was incidence of the composite of severe bleeding according to the Bleeding Academic Research Consortium (BARC)-4 definition that includes: intracranial bleeding; re-operation for bleeding; transfusion ≥ 5 units of packed red blood cells (pRBC) and 24-hour chest tube drainage of ≥ 2 liters. Additional individual outcomes included the rate of large transfusion events (≥ 5 units of pRBC) and the rate of re-operation for bleeding. BARC-4 bleeding was significantly reduced with the use of the device (10.7% vs. 33% control, p<0.001) as were large transfusion events (6% vs. 27% control, p<0.001) and re-operations for bleeding (4% vs. 9.6% control, p=0.02). Mortality at 30 days was not different between the 2 groups (4.4% vs. 6.5%, p=ns). Importantly, there were no device deficiencies or device-related adverse events reported by participating centers, underscoring the ease and safety of the use of the device in the real world. About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorbents' lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with more than a quarter million devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved or cleared in the United States. In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. In September 2024, the Company submitted a De Novo Request to the U.S. FDA requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the antithrombotic drug ticagrelor, which was accepted for substantive review in October 2024. On April 25, 2025, the FDA issued a denial letter regarding the Company's De Novo Request for DrugSorb-ATR, identifying remaining deficiencies that must be addressed before the De Novo Request can be granted, and the device can be authorized for commercialization in the U.S. The Company believes these items can be most effectively and expeditiously resolved through the formal appeal process, which facilitates engagement with FDA senior leadership and our external surgical experts. Given the expedited timelines associated with the appeal process, the Company believes that a final regulatory decision can be achieved in 2025. In November 2024, the Company received its MDSAP certification and submitted its Medical Device License (MDL) application to Health Canada. CytoSorbents' DrugSorb-ATR application with Health Canada remains under advanced review. While Health Canada has indicated that application reviews are currently delayed beyond their target Market Authorization Times (MAT) due to a backlog, they have reaffirmed their commitment to issuing a decision at the earliest opportunity. The Company remains confident in receiving a final regulatory decision in 2025. DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company's website at or follow us on Facebook and X. Forward-Looking Statements This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, our ability to resolve deficiencies in the FDA denial letter through a successfully appeal the FDA's decision, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2025, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. Please Click to Follow Us on Facebook and X U.S. Company Contact: Peter J. Mariani, Chief Financial Officer 305 College Road East Princeton, NJ 08540 [email protected] Investor Relations Contact: Aman Patel, CFA & Adanna G. Alexander, PhD ICR Healthcare [email protected] SOURCE Cytosorbents Corp WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED